Mild Cognitive ImpairmentKodroSolNCT02087618
The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment
A study testing Kodro+ and Kodro+D in people with Mild Cognitive Impairment, run by Mt. Sinai Medical Center, Miami at 1 site in United States.
Trial summary
This is a pilot study to examine the feasibility of a formal 30-minute daily program on a tablet computer (simply a "tablet") in subjects with mild cognitive impairment (MCI). The purpose of the program, known as Kodro Solution, is to increase physical activity, maintain social interaction, improve nutrition and… Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Mild Cognitive Impairment
- What is being tested?
- Kodro+ and Kodro+D
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2014to Jun 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of Mild Cognitive Impairment as defined below:
- Clinical Dementia Rating (CDR) global score = 0.5 (Morris 1993)
- MMSE > 20
- Diagnostic and Statistical Manual of Mental Disorders, Version 4, Text Revised (DSM-IV-TR) criteria of dementia not fulfilled (Appendix II)
- 60 years and older
- Subjective memory complaints
Show all 11Show fewer
- Able to use Kodro by him/her self or with minimal assistance from the study partner
- Understands English at an 8th grade proficiency level
- Wifi access in the subject's home
- Willing and able to connect to Kodro for a minimum of 30 minutes daily
- Study partner able to fill in the self-report questionnaires during visits and supervise the subject as needed
Who cannot join
- MMSE < 20
- Motor or sensory disorders limiting the manipulation of an tablet
- Any involvement with brain-based programs during the study (e.g., Posit Science, Luminosity)
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Ranjan Duara, MD
About this study
Official title: The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment (Kodro Solution)
This is a pilot study to examine the feasibility of a formal 30-minute daily program on a tablet computer (simply a "tablet") in subjects with mild cognitive impairment (MCI). The purpose of the program, known as Kodro Solution, is to increase physical activity, maintain social interaction, improve nutrition and exercise cognitive skills using a tablet. In addition to feasibility, outcome measures will include: (a) health-related quality of life, (b) self-esteem, (c) activities of daily living, (d) socialization, (e) mood, and (f) cognition. Study participants must have a study partner who can assist them with training on use of the tablet and the Kodro Solution program.
Fifty (50) study subjects and their study partners will be recruited at the Wien Center. A delayed start design will be utilized. Study subjects will be randomly assigned to either active treatment (Kodro+) or delayed treatment (Kodro+D). Active treatment with Kodro Solution will be initiated at the baseline visit for Kodro+ subjects and 12 weeks after baseline for Kodro+D subjects. The 12-week period without tablets will serve as a control. Active treatment with Kodro Solution will continue for 36 weeks for the Kodro+ subjects and 24 weeks for the Kodro+D subjects. For both groups, the outcome measures will be assessed at baseline, week 12 and week 36. The lagged design will facilitate enrollment and enable the assessment of a dose effect.
Read the detailed description
Background: Due to increased longevity and aging of the baby boomer, the number of older persons with cognitive disorders such as Alzheimer's Disease (AD) is increasing rapidly. It is uncertain whether cognitive and memory training intervention programs can delay the onset or reduce the risk for the subsequent development of AD, but several studies have shown that cognitive training in people with Mild Cognitive Impairment (MCI) has a moderate effect on memory.
A tablet-based platform known as Kodro was developed in 2011 by a French company to improve multiple domains, including memory and quality of life, among older persons with and without memory disorders. The goals of the program are to increase physical activity, maintain social interaction, improve nutrition and exercise cognitive skills. The program requires internet access to enable connection with the program, family and friends, other Kodro users and external experts. The version of Kodro in this study, Kodro Solution, was designed for seniors with mild cognitive impairment or very mild dementia, who are living at home. Kodro Solution is customized to each user's interests and hobbies. For example, a user with an interest in cuisine might be presented with a brief video about the top toppings for hamburgers; this user would then be asked 5 questions to test his/her memory.
Purpose: To determine whether Kodro solution is feasible among older people with MCI. The secondary aim is to measure the effect of Kodro on cognition, mood, activities of daily living and quality of life.
Procedures Subjects: Potential subjects will be selected from patients diagnosed with MCI at the Wien Center who are at least 60 years of age. Subjects will be required to have a wireless connection to the internet and a study partner. The subject should be capable of learning to use the tablet and Kodro system with minimal assistance from the study partner (friend or family member). The role of the study partner is to assist the staff with the assessment of the subject and to assist the subject with study visits and the use of Kodro.
Baseline Visit and Randomization: After a subject has been consented and deemed eligible for the study, he/she will be randomized to either a group with Kodro at baseline ("Kodro+") or a group with Kodro delayed until 12 weeks post-baseline ("Kodro+D"). Study raters will be blind to subject's randomization.
Intervention: Subjects in the Kodro+ group will be trained on the use of the tablet and Kodro at the baseline visit, and will continue using Kodro for 36 weeks. Subjects in the Kodro+D group will be trained on the tablet and Kodro at 12 weeks, and will continue to use Kodro for 24 weeks. Participants will be expected to log in and utilize the program for a minimum of 30 minutes daily. The participants will perform various activities such as reading newspaper articles, books, listening to audio tapes, watching video clips, and playing games. Information regarding the participant's usage of the program and how well they perform on the activities is stored on Kodro's secure server. The program is customized to the user's level and the information obtained will gauge the level of difficulty as well as appropriateness of activities that are offered daily to the participant.
Assessments: The subjects' use of Kodro will be collected continuously throughout the study via a secure server in France. There will not be any identifying information collected such as name, address, etc. The data collected will include frequency of use, diversity of activities and scores on activities.
Assessments of cognition, mood, activities of daily living and quality of life will be done at the baseline visit, 12-week visit and the final 36-week visit.
Statistical Analysis The main outcome measure will be the drop-out rate and use of Kodro. The secondary outcome measures will be scores on tests of cognition, mood, quality of life and activities of daily living.
- Conditions
- Mild Cognitive Impairment
- Being tested
- Kodro+, Kodro+D
- Keywords
- MCI, Alzheimer's, Dementia, Tablet, Non-Pharmacological Intervention, Cognition
- Medical subject headings
- Cognitive Dysfunction, Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Kodro+Other
Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
Kodro+DOther
Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
| Study group | Role | What they receive |
|---|---|---|
| Kodro+ | Active comparator | Will begin Kodro program at baseline Receives: Other: Kodro+ |
| Kodro+D | Placebo comparator | Will begin Kodro program 12-weeks post baseline Receives: Other: Kodro+D |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compliance with Kodro Solution
Compliance with the Kodro Solution program will be assessed using:
- Frequency of use (average days per week, average hours per day)
Measured: 36 weeks
Secondary outcomes (1)
Satisfaction with Kodro Solution
Questionnaires given to both the participant and study partner.
Measured: 36-weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2014 (estimated)
- Study startMar 2014
- Primary completionMar 2015 (estimated)
- Study completionJun 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mt. Sinai Medical Center, Miami
- Sponsor type
- University, hospital or other
- Collaborators
- Kodro Inc.
- Responsible party
- Principal investigator, Ranjan Duara, MD, Mt. Sinai Medical Center, Miami
- Investigators
- Ranjan Duara, MD, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02087618
- Sponsor's protocol ID
- 14-05-H-02
- Acronym
- KodroSol
- Status last verified
- Mar 2014
- First submitted
- 6 Mar 2014
- Last updated
- 14 Mar 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment (Kodro Solution)
- ClinicalTrials.gov ID
- NCT02087618
- Acronym / sponsor ID
- KodroSol / 14-05-H-02
- Conditions
- Mild Cognitive Impairment
- Keywords
- MCI, Alzheimer's, Dementia, Tablet, Non-Pharmacological Intervention, Cognition
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Mt. Sinai Medical Center, MiamiUniversity, hospital or other
- Collaborators
- Kodro Inc.
- Study start
- Mar 2014
- Primary completion
- Mar 2015 (estimated)
- Study completion
- Jun 2015 (estimated)
- First posted
- 14 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot study to examine the feasibility of a formal 30-minute daily program on a tablet computer (simply a "tablet") in subjects with mild cognitive impairment (MCI). The purpose of the program, known as Kodro Solution, is to increase physical activity, maintain social interaction, improve nutrition and exercise cognitive skills using a tablet. In addition to feasibility, outcome measures will include: (a) health-related quality of life, (b) self-esteem, (c) activities of daily living, (d) socialization, (e) mood, and (f) cognition. Study participants must have a study partner who can assist them with training on use of the tablet and the Kodro Solution program.
Fifty (50) study subjects and their study partners will be recruited at the Wien Center. A delayed start design will be utilized. Study subjects will be randomly assigned to either active treatment (Kodro+) or delayed treatment (Kodro+D). Active treatment with Kodro Solution will be initiated at the baseline visit for Kodro+ subjects and 12 weeks after baseline for Kodro+D subjects. The 12-week period without tablets will serve as a control. Active treatment with Kodro Solution will continue for 36 weeks for the Kodro+ subjects and 24 weeks for the Kodro+D subjects. For both groups, the outcome measures will be assessed at baseline, week 12 and week 36. The lagged design will facilitate enrollment and enable the assessment of a dose effect.
Detailed description
Background: Due to increased longevity and aging of the baby boomer, the number of older persons with cognitive disorders such as Alzheimer's Disease (AD) is increasing rapidly. It is uncertain whether cognitive and memory training intervention programs can delay the onset or reduce the risk for the subsequent development of AD, but several studies have shown that cognitive training in people with Mild Cognitive Impairment (MCI) has a moderate effect on memory.
A tablet-based platform known as Kodro was developed in 2011 by a French company to improve multiple domains, including memory and quality of life, among older persons with and without memory disorders. The goals of the program are to increase physical activity, maintain social interaction, improve nutrition and exercise cognitive skills. The program requires internet access to enable connection with the program, family and friends, other Kodro users and external experts. The version of Kodro in this study, Kodro Solution, was designed for seniors with mild cognitive impairment or very mild dementia, who are living at home. Kodro Solution is customized to each user's interests and hobbies. For example, a user with an interest in cuisine might be presented with a brief video about the top toppings for hamburgers; this user would then be asked 5 questions to test his/her memory.
Purpose: To determine whether Kodro solution is feasible among older people with MCI. The secondary aim is to measure the effect of Kodro on cognition, mood, activities of daily living and quality of life.
Procedures Subjects: Potential subjects will be selected from patients diagnosed with MCI at the Wien Center who are at least 60 years of age. Subjects will be required to have a wireless connection to the internet and a study partner. The subject should be capable of learning to use the tablet and Kodro system with minimal assistance from the study partner (friend or family member). The role of the study partner is to assist the staff with the assessment of the subject and to assist the subject with study visits and the use of Kodro.
Baseline Visit and Randomization: After a subject has been consented and deemed eligible for the study, he/she will be randomized to either a group with Kodro at baseline ("Kodro+") or a group with Kodro delayed until 12 weeks post-baseline ("Kodro+D"). Study raters will be blind to subject's randomization.
Intervention: Subjects in the Kodro+ group will be trained on the use of the tablet and Kodro at the baseline visit, and will continue using Kodro for 36 weeks. Subjects in the Kodro+D group will be trained on the tablet and Kodro at 12 weeks, and will continue to use Kodro for 24 weeks. Participants will be expected to log in and utilize the program for a minimum of 30 minutes daily. The participants will perform various activities such as reading newspaper articles, books, listening to audio tapes, watching video clips, and playing games. Information regarding the participant's usage of the program and how well they perform on the activities is stored on Kodro's secure server. The program is customized to the user's level and the information obtained will gauge the level of difficulty as well as appropriateness of activities that are offered daily to the participant.
Assessments: The subjects' use of Kodro will be collected continuously throughout the study via a secure server in France. There will not be any identifying information collected such as name, address, etc. The data collected will include frequency of use, diversity of activities and scores on activities.
Assessments of cognition, mood, activities of daily living and quality of life will be done at the baseline visit, 12-week visit and the final 36-week visit.
Statistical Analysis The main outcome measure will be the drop-out rate and use of Kodro. The secondary outcome measures will be scores on tests of cognition, mood, quality of life and activities of daily living.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Kodro+ | Active comparator | Other: Kodro+Will begin Kodro program at baseline |
| Kodro+D | Placebo comparator | Other: Kodro+DWill begin Kodro program 12-weeks post baseline |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Diagnosis of Mild Cognitive Impairment as defined below:
- Clinical Dementia Rating (CDR) global score = 0.5 (Morris 1993)
- MMSE > 20
- Diagnostic and Statistical Manual of Mental Disorders, Version 4, Text Revised (DSM-IV-TR) criteria of dementia not fulfilled (Appendix II)
- 60 years and older
Key exclusion criteria (3 listed)
- MMSE < 20
- Motor or sensory disorders limiting the manipulation of an tablet
- Any involvement with brain-based programs during the study (e.g., Posit Science, Luminosity)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Kodro+Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks | Other | Kodro+ |
| Kodro+DKodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks | Other | Kodro+D |
Primary outcome
Compliance with Kodro Solution
Time frame: 36 weeks
Compliance with the Kodro Solution program will be assessed using: • Frequency of use (average days per week, average hours per day)
1 secondary outcome
Satisfaction with Kodro Solution
Time frame: 36-weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2014.
Related trials for Mild Cognitive Impairment
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingPhase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Alzheimer Disease
Recruiting
Non-invasive Brain Stimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Parkinson Disease, Mild Cognitive Impairment
RecruitingObservational study
Loneliness as Risk Factor for Dementia
Mild Cognitive Impairment (MCI), Dementia (Diagnosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ranjan Duara, MD principal investigator
Icahn School of Medicine at Mount Sinai
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Kodro+ and Kodro+D in people with Mild Cognitive Impairment, run by Mt. Sinai Medical Center, Miami at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sarine Salama, LMHC (305-674-2121 ext. 55706, Sarine.Salama@msmc.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compliance with Kodro Solution (time frame: 36 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2014.